CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Curis, Inc.
Curis, Inc.
AVM Biotechnology Inc
Georgetown University
Assistance Publique - HĂ´pitaux de Paris
Cellectar Biosciences, Inc.
Center for International Blood and Marrow Transplant Research
Cancer Research UK
M.D. Anderson Cancer Center
Center for International Blood and Marrow Transplant Research
AbbVie
Cancer Research UK
Cancer Research UK
Cancer Research UK
UNC Lineberger Comprehensive Cancer Center
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Dana-Farber Cancer Institute
Baylor College of Medicine
Baylor College of Medicine
Barbara Ann Karmanos Cancer Institute
UNC Lineberger Comprehensive Cancer Center
Zhejiang DTRM Biopharma
Case Comprehensive Cancer Center
Celgene
Amgen
University of Haifa
AO GENERIUM
Celgene
Children's Oncology Group
Takeda
Hospices Civils de Lyon
Incyte Corporation
Rutgers, The State University of New Jersey
Northwestern University
AbbVie
University of California, San Francisco
University of Michigan Rogel Cancer Center
M.D. Anderson Cancer Center
Jonsson Comprehensive Cancer Center
Case Comprehensive Cancer Center
Amgen Research (Munich) GmbH
Baylor College of Medicine
Baylor College of Medicine
LEO Pharma
National Institutes of Health Clinical Center (CC)
Mayo Clinic
Barbara Ann Karmanos Cancer Institute
Nordic Nanovector
University of Texas Southwestern Medical Center
University of North Carolina, Chapel Hill
Alliance for Clinical Trials in Oncology